Radiation after CAR-T: a new hope for myeloma patients?

NCT ID NCT05336383

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether radiation therapy can help control multiple myeloma that remains active after standard CAR-T cell therapy. About 30 adults who still have signs of myeloma on scans after CAR-T will receive targeted radiation to up to five tumor spots. Researchers will measure how many patients respond and how long the response lasts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiation therapy
What this could lead to: If it works, this could offer a way to control multiple myeloma that remains active after CAR-T therapy, potentially improving outcomes for patients.
What could go wrong: This is a small, early-phase study (30 people) testing a new combination. It may not show clear benefit, and radiation can have side effects like fatigue or skin irritation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT PLASMA CELL NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT PLASMA CELL NEOPLASM MULTIPLE MYELOMA PLASMA CELL NEOPLASM

Contacts and locations

Locations

M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.